Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Paul Benn

Showing results (11-20 of 20) with videos related to

Pageof 2
Sort By:
You have reached the last page of results.This site can display upto 20 results.
International Journal of STD & AIDS|February 9, 2006
UK Guideline for the use of post-exposure prophylaxis for HIV following sexual exposureMartin Fisher, Paul Benn, Barry Evans, et al.
International Journal of STD & AIDS|September 20, 2023
<i>Trypanosoma cruzi</i> screening in people living with HIV in the UKNadia Ahmed, Sophie Herbert, Alejandro Arenas-Pinto, et al.
The Journal of Antimicrobial Chemotherapy|April 4, 2017
Randomized controlled trial of the tolerability and completion of maraviroc compared with Kaletra® in combination with Truvada® for HIV post-exposure prophylaxis (MiPEP Trial)Ana Milinkovic, Paul Benn, Alejandro Arenas-Pinto, et al.
Infectious Diseases and Therapy|April 26, 2025
Clinical Pharmacokinetics and Safety of a New HIV-1 Capsid Inhibitor, VH4004280, After Oral Administration in Adults Without HIVNilay Thakkar, Rulan Griesel, Amy Pierce, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|September 12, 2022
Brief Report: Impact of COVID-19 on Cabotegravir Plus Rilpivirine Long-Acting Dosing Across 6 Ongoing Global Phase IIb and III Clinical TrialsMaggie Czarnogorski, Paul Benn, Cindy McCoig, et al.
Infectious Diseases and Therapy|April 2, 2025
Clinical Pharmacokinetics and Safety of Orally Administered VH4011499, a New HIV-1 Capsid Inhibitor, in Adults Without HIVNilay Thakkar, Rulan Griesel, Amy Pierce, et al.
International Journal of STD & AIDS|June 22, 2021
Using Climate-HIV to describe real-world clinical outcomes for people living with HIV taking dolutegravir-based regimensChinyere Okoli, Achim Schwenk, Matthew Radford, et al.
Clinical Pharmacology in Drug Development|April 29, 2025
A Randomized Phase 1 Study Evaluating Pharmacokinetics, Safety, and Tolerability of a High-Concentration, Long-Acting Cabotegravir Formulation in Adults Without HIVKelong Han, Paul Benn, Jörg Sievers, et al.
AIDS (London, England)|July 14, 2021
Week 96 extension results of a Phase 3 study evaluating long-acting cabotegravir with rilpivirine for HIV-1 treatmentSusan Swindells, Thomas Lutz, Lelanie Van Zyl, et al.
Lancet (London, England)|December 14, 2020
Long-acting cabotegravir and rilpivirine dosed every 2 months in adults with HIV-1 infection (ATLAS-2M), 48-week results: a randomised, multicentre, open-label, phase 3b, non-inferiority studyEdgar T Overton, Gary Richmond, Giuliano Rizzardini, et al.
Pageof 2

Showing results (11-20 of 20) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 20 results.
International Journal of STD & AIDS|February 9, 2006
UK Guideline for the use of post-exposure prophylaxis for HIV following sexual exposureMartin Fisher, Paul Benn, Barry Evans, et al.
International Journal of STD & AIDS|September 20, 2023
<i>Trypanosoma cruzi</i> screening in people living with HIV in the UKNadia Ahmed, Sophie Herbert, Alejandro Arenas-Pinto, et al.
The Journal of Antimicrobial Chemotherapy|April 4, 2017
Randomized controlled trial of the tolerability and completion of maraviroc compared with Kaletra® in combination with Truvada® for HIV post-exposure prophylaxis (MiPEP Trial)Ana Milinkovic, Paul Benn, Alejandro Arenas-Pinto, et al.
Infectious Diseases and Therapy|April 26, 2025
Clinical Pharmacokinetics and Safety of a New HIV-1 Capsid Inhibitor, VH4004280, After Oral Administration in Adults Without HIVNilay Thakkar, Rulan Griesel, Amy Pierce, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|September 12, 2022
Brief Report: Impact of COVID-19 on Cabotegravir Plus Rilpivirine Long-Acting Dosing Across 6 Ongoing Global Phase IIb and III Clinical TrialsMaggie Czarnogorski, Paul Benn, Cindy McCoig, et al.
Infectious Diseases and Therapy|April 2, 2025
Clinical Pharmacokinetics and Safety of Orally Administered VH4011499, a New HIV-1 Capsid Inhibitor, in Adults Without HIVNilay Thakkar, Rulan Griesel, Amy Pierce, et al.
International Journal of STD & AIDS|June 22, 2021
Using Climate-HIV to describe real-world clinical outcomes for people living with HIV taking dolutegravir-based regimensChinyere Okoli, Achim Schwenk, Matthew Radford, et al.
Clinical Pharmacology in Drug Development|April 29, 2025
A Randomized Phase 1 Study Evaluating Pharmacokinetics, Safety, and Tolerability of a High-Concentration, Long-Acting Cabotegravir Formulation in Adults Without HIVKelong Han, Paul Benn, Jörg Sievers, et al.
AIDS (London, England)|July 14, 2021
Week 96 extension results of a Phase 3 study evaluating long-acting cabotegravir with rilpivirine for HIV-1 treatmentSusan Swindells, Thomas Lutz, Lelanie Van Zyl, et al.
Lancet (London, England)|December 14, 2020
Long-acting cabotegravir and rilpivirine dosed every 2 months in adults with HIV-1 infection (ATLAS-2M), 48-week results: a randomised, multicentre, open-label, phase 3b, non-inferiority studyEdgar T Overton, Gary Richmond, Giuliano Rizzardini, et al.
Pageof 2